FR3120877B1 - Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations - Google Patents

Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations Download PDF

Info

Publication number
FR3120877B1
FR3120877B1 FR2102805A FR2102805A FR3120877B1 FR 3120877 B1 FR3120877 B1 FR 3120877B1 FR 2102805 A FR2102805 A FR 2102805A FR 2102805 A FR2102805 A FR 2102805A FR 3120877 B1 FR3120877 B1 FR 3120877B1
Authority
FR
France
Prior art keywords
receptor
grafted
fibrin
antibody
hybrid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2102805A
Other languages
English (en)
Other versions
FR3120877A1 (fr
Inventor
Cyril Clavel
Guy Serre
Pierre Martineau
Nerea Allende-Vega
Florence Apparailly
Martin Villalba
Christian Jorgensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Montpellier
Centre Hospitalier Universitaire de Toulouse
Universite de Montpellier
Arthritis Recherche et Developpement SAS
Universite de Toulouse
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Montpellier
Centre Hospitalier Universitaire de Toulouse
Universite de Montpellier
Universite Toulouse III Paul Sabatier
Arthritis Recherche et Developpement SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Montpellier, Centre Hospitalier Universitaire de Toulouse, Universite de Montpellier, Universite Toulouse III Paul Sabatier, Arthritis Recherche et Developpement SAS filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR2102805A priority Critical patent/FR3120877B1/fr
Priority to PCT/FR2022/050506 priority patent/WO2022195239A1/fr
Priority to EP22715349.1A priority patent/EP4308690A1/fr
Priority to US18/551,156 priority patent/US20240307538A1/en
Publication of FR3120877A1 publication Critical patent/FR3120877A1/fr
Application granted granted Critical
Publication of FR3120877B1 publication Critical patent/FR3120877B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L’invention concerne une cellule immunitaire comprenant au moins un récepteur Fc à sa surface, caractérisée en ce qu’une molécule hybride est greffée au niveau du récepteur Fc, ladite molécule hybride comprenant au moins un fragment Fc d’anticorps lié de façon covalente à au moins un peptide dérivé de fibrine comprenant un ou plusieurs résidu(s) citrullyl. La présente invention concerne également les utilisations d’une telle cellule greffée, ainsi que son procédé de production. (pas de figure)
FR2102805A 2021-03-19 2021-03-19 Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations Active FR3120877B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR2102805A FR3120877B1 (fr) 2021-03-19 2021-03-19 Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations
PCT/FR2022/050506 WO2022195239A1 (fr) 2021-03-19 2022-03-18 Cellule immunitaire comprenant un recepteur fc a sa surface, et sur lequel est greffe une molecule hybride comprenant un fragment fc d'anticorps et au moins un peptide citrulline derive de la fibrine, et ses utilisations
EP22715349.1A EP4308690A1 (fr) 2021-03-19 2022-03-18 Cellule immunitaire comprenant un recepteur fc a sa surface, et sur lequel est greffe une molecule hybride comprenant un fragment fc d'anticorps et au moins un peptide citrulline derive de la fibrine, et ses utilisations
US18/551,156 US20240307538A1 (en) 2021-03-19 2022-03-18 Immune cell which has an fc receptor on its surface and to which is grafted a hybrid molecule comprising an antibody fc fragment and at least one fibrin-derived citrulline peptide, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2102805 2021-03-19
FR2102805A FR3120877B1 (fr) 2021-03-19 2021-03-19 Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations

Publications (2)

Publication Number Publication Date
FR3120877A1 FR3120877A1 (fr) 2022-09-23
FR3120877B1 true FR3120877B1 (fr) 2025-03-14

Family

ID=77999011

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2102805A Active FR3120877B1 (fr) 2021-03-19 2021-03-19 Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations

Country Status (4)

Country Link
US (1) US20240307538A1 (fr)
EP (1) EP4308690A1 (fr)
FR (1) FR3120877B1 (fr)
WO (1) WO2022195239A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900657B1 (fr) * 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JP6865584B2 (ja) 2013-12-23 2021-04-28 コヴァラブ 化合物の共有結合性コンジュゲーションのためのｍＴＧ基質
JP7540877B2 (ja) 2016-02-12 2024-08-27 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインの生成方法

Also Published As

Publication number Publication date
WO2022195239A1 (fr) 2022-09-22
US20240307538A1 (en) 2024-09-19
EP4308690A1 (fr) 2024-01-24
FR3120877A1 (fr) 2022-09-23

Similar Documents

Publication Publication Date Title
Jones et al. “High‐risk” host cell proteins (HCPs): A multi‐company collaborative view
ES2627334T3 (es) Endoglucosidasa de streptococcus pyogenes y métodos para usarla
Gudmann et al. Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease
MA49971B1 (fr) Vésicules extracellulaires modifiées et leurs utilisations
EP2016422B1 (fr) Detection des maladies veineuses thromboemboliques par le dosage des d-dimeres et de la fibrine soluble
Kozik et al. Kinin release from human kininogen by 10 aspartic proteases produced by pathogenic yeast Candida albicans
El-Awar et al. HLA class II DQA and DQB epitopes: recognition of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines
RU2522231C1 (ru) Способ диагностики онкологических заболеваний и иммуноферментный набор для его осуществления
FR3120877B1 (fr) Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations
KR20190126052A (ko) 당쇄를 갖는 물질과 렉틴과의 복합체 형성 방법
FR3062395B1 (fr) Microorganisme genetiquement optimise pour la production de molecules d'interet
Lexhaller et al. Identification of isopeptides between human tissue transglutaminase and wheat, rye, and barley gluten peptides
van Rijswijck et al. Direct comparison of the hinge-cleaving proteases IgdE and BdpK for LC-MS-based IgG1 clonal profiling
Alptekin et al. From glomalin to glomalose: unraveling the molecular identity of the MAb32B11 antigen
Stufano et al. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination
FR3120865B1 (fr) Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations
FR3139821B1 (fr) Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations
FR3147289B1 (fr) Aptamère composite et son utilisation pour détecter une molécule d’intérêt
FR3113053B1 (fr) Ensemble d’atomes de carbone a l’etat d’hybridation sp2fonctionnalisé, son procede de preparation et ses utilisations, notamment pour rendre une surface antibacterienne
US20190265257A1 (en) Measurement reagent for cross-linked fibrin degradation product, and measurement method
WO2002018628A1 (fr) Methode de dosage de la fibrine soluble
KR20140028529A (ko) 링커 폴리펩티드 및 이를 이용한 표적 물질 분석 방법
Milanowski et al. Genetic variability of SRC family kinases and its association with platelet hyperreactivity and clinical outcomes: a systematic review
FR3139820B1 (fr) Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une vascularite auto-immune, et ses utilisations
US9244073B2 (en) Assays for detecting enzymatic activity

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220923

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6